Clinical Trials
27 trialsNCT07100080 2026-05-27
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT05987956 2026-05-22
Drugs-SNPs
Medicine Invention Design, Inc
Phase 2/3 Active not recruiting
NCT06712316 2026-05-22
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
BioNTech SE
Phase 2/3 Recruiting
NCT04613596 2026-05-20
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Mirati Therapeutics Inc.
Phase 2/3 Recruiting
NCT07365319 2026-05-20
TeLuRide-008
Eikon Therapeutics
Phase 2/3 Recruiting
NCT07155187 2026-03-11
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie
Phase 2/3 Recruiting
NCT03178552 2026-03-09
B-FAST
Hoffmann-La Roche
Phase 2/3 Active not recruiting
NCT06236438 2026-02-23
LIVIGNO-4
AbbVie
Phase 2/3 Recruiting
NCT04619797 2026-02-03
SKYSCRAPER-06
Hoffmann-La Roche
Phase 2/3 Completed
NCT06984588 2026-01-30
A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
TJ Biopharma Co., Ltd.
Phase 2/3 Active not recruiting
NCT05800015 2026-01-22
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
Regeneron Pharmaceuticals
Phase 2/3 Active not recruiting
NCT05020769 2025-09-26
SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3 Active not recruiting
NCT03653546 2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3 Completed
NCT04206072 2025-08-11
D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC
Betta Pharmaceuticals Co., Ltd.
Phase 2/3 Completed
NCT06417008 2025-08-01
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
Hansoh BioMedical R&D Company
Phase 2/3 Recruiting
NCT00518869 2025-06-04
Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue
PhytoHealth Corporation
Phase 2/3 Terminated
NCT05661240 2022-12-22
Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields (EFE-P100)Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1(PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Phase 2/3 Unknown
NCT01905657 2021-10-06
MK-3475-010
Merck Sharp & Dohme LLC
Phase 2/3 Completed
NCT03288870 2020-10-29
DOMINUS
Biocad
Phase 2/3 Unknown
NCT01774578 2020-05-28
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Lumos Pharma
Phase 2/3 Terminated
NCT02186301 2019-05-07
EGFR
Clovis Oncology, Inc.
Phase 2/3 Terminated
NCT02388919 2017-09-18
ALTER0303
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2/3 Completed
NCT01383148 2017-01-05
TIME
Transgene
Phase 2/3 Terminated
NCT02029209 2016-12-16
To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2/3 Unknown
NCT01348126 2015-11-05
GALAXY
Synta Pharmaceuticals Corp.
Phase 2/3 Terminated
NCT00415818 2014-07-16
Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer
Transgene
Phase 2/3 Completed
NCT00516685 2011-09-30
NSCLC
Bioven Sdn. Bhd.
Phase 2/3 Terminated